Aurisco Pharmaceutical Co.,Ltd.

605116

CNE1000042S4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
22.64 ^CNY	+1.98%		+0.80%	-12.32%

2023	Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2023.	CI

Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 million.

September 10, 2020 at 12:00 am EDT

Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 million. Security Name: A Shares Security Type: Common Stock Securities Offered: 41,000,000 PriceRange: CNY 8.37

Latest news about Aurisco Pharmaceutical Co.,Ltd.

Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2023.	23-09-20	CI
Aurisco Pharmaceutical Co.,Ltd.(XSSC:605116) added to S&P Global BMI Index	23-09-18	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China	23-06-27	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Aurisco Cooperates with Cytiva to Build Its First Oligo Flexfactory for Commercial Production	23-01-05	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2022.	22-09-20	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Huayi Boao Quantum Technology Co., Ltd. announced that it has received CNY 100 million in funding from Aurisco Pharmaceutical Co.,Ltd., Gaorong Capital, Sequoia China Investment Management LLP, Turing Ventures, Qiji Chuangtan Investment Management Co., Ltd.	22-04-21	CI
Huayi Quantum announced that it has received CNY 15.5 million in funding from Gaorong Capital, Sequoia China Investment Management LLP, Qiji Chuangtan Investment Management Co., Ltd., Turing Ventures, Aurisco Pharmaceutical Co.,Ltd.	22-04-21	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2021.	21-09-20	CI
Aurisco Pharmaceutical Co.,Ltd.(SHSE:605116) added to Shanghai Stock Exchange A Share Index	21-09-20	CI
Aurisco Pharmaceutical Co.,Ltd.(SHSE:605116) added to Shanghai Stock Exchange Composite Index	21-09-20	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Aurisco Pharmaceutical Co.,Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-19	CI
Yangzhou Aurisco Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Aurisco Pharmaceutical Co.,Ltd.	20-10-28	CI
Aurisco Pharmaceutical Co.,Ltd. Announces Major Financial Indicators in 1St Three Quarters of 2020	20-10-27	CI
Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 million.	20-09-10	CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-09-09	CI

Chart Aurisco Pharmaceutical Co.,Ltd.

Duration

Period

More charts

Aurisco Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Aurisco Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.64 CNY

Average target price

31 CNY

Spread / Average Target

+36.93%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AURISCO PHARMACEUTICAL CO.,LTD.	-12.32%	1.27B
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+24.18%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.17%	211B
NOVARTIS AG	-0.29%	203B
ROCHE HOLDING AG	-10.10%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals